Compare BY & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BY | TSHA |
|---|---|---|
| Founded | 1914 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 2017 | 2020 |
| Metric | BY | TSHA |
|---|---|---|
| Price | $30.30 | $4.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $33.50 | $10.56 |
| AVG Volume (30 Days) | 131.5K | ★ 2.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.55% | N/A |
| EPS Growth | 5.09 | ★ 62.50 |
| EPS | ★ 2.89 | N/A |
| Revenue | N/A | ★ $8,333,000.00 |
| Revenue This Year | $17.06 | N/A |
| Revenue Next Year | $2.84 | N/A |
| P/E Ratio | $10.55 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $22.63 | $1.13 |
| 52 Week High | $33.89 | $6.02 |
| Indicator | BY | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 37.29 | 48.07 |
| Support Level | $28.44 | $4.39 |
| Resistance Level | $31.24 | $5.16 |
| Average True Range (ATR) | 0.76 | 0.19 |
| MACD | -0.18 | 0.01 |
| Stochastic Oscillator | 16.21 | 65.06 |
Byline Bancorp Inc is the holding company for Byline Bank, a full-service commercial bank serving small-and-medium sized businesses, financial sponsors, and consumers. The company offers a broad range of banking products and services to small and medium sized businesses, commercial real estate and online account opening to consumer and business. Also provide trust and wealth management services to its customers. In addition to traditional commercial banking business, company provide small ticket equipment leasing solutions through Byline Financial Group, a wholly-owned subsidiary of Byline Bank.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.